Abstract
This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation. (Registered at clinicaltrials.gov identifier: 01142674).
| Original language | English |
|---|---|
| Pages (from-to) | 1191-1197 |
| Number of pages | 7 |
| Journal | Haematologica |
| Volume | 103 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 3 2018 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
The outcome of peripheral t-cell lymphoma patients failing first-line therapy : A report from the prospective, international t-cell project. / International T-cell Project Network.
In: Haematologica, Vol. 103, No. 7, 03.07.2018, p. 1191-1197.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The outcome of peripheral t-cell lymphoma patients failing first-line therapy
T2 - A report from the prospective, international t-cell project
AU - International T-cell Project Network
AU - Bellei, Monica
AU - Foss, Francine M.
AU - Shustov, Andrei R.
AU - Horwitz, Steven M.
AU - Marcheselli, Luigi
AU - Kim, Won Seog
AU - Cabrera, Maria E.
AU - Dlouhy, Ivan
AU - Nagler, Arnon
AU - Advani, Ranjana H.
AU - Pesce, Emanuela A.
AU - Ko, Young Hyeh
AU - Martinez, Virginia
AU - Montoto, Silvia
AU - Chiattone, Carlos
AU - Moskowitz, Alison
AU - Spina, Michele
AU - Biasoli, Irene
AU - Manni, Martina
AU - Federico, Massimo
PY - 2018/7/3
Y1 - 2018/7/3
N2 - This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation. (Registered at clinicaltrials.gov identifier: 01142674).
AB - This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation. (Registered at clinicaltrials.gov identifier: 01142674).
UR - http://www.scopus.com/inward/record.url?scp=85049591059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049591059&partnerID=8YFLogxK
U2 - 10.3324/haematol.2017.186577
DO - 10.3324/haematol.2017.186577
M3 - Article
VL - 103
SP - 1191
EP - 1197
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 7
ER -